California women’s health company Minerva Surgical is just a stone’s throw from wrapping up an equity funding round slated to bring in $25.6 million.
Minerva is looking for just $5,840 more, according to an SEC filing dated Sept. 22. The round has brought in 26 unnamed investors so far.
Minerva, founded in 2008, is developing technologies for treatment of abnormal uterine bleeding or heavy periods, a condition that affects as many as 20% of women, according to the company’s website. Minerva’s flagship device is the Aurora endometrial ablation system, which targets and eliminates the endometrial lining in a procedure that takes as little as 4 minutes.
The company is currently evaluating the Aurora system in a 153-patient clinical trial launched in 2012, expecting to hit primary completion in November.
The latest funding round, the company’s 1st since 2012, puts Minerva at about $80 million in reported funding, according to SEC filings.
